Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...
Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the ...
Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...
Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...
Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...
The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
As has been widely acknowledged, one of the most meaningful steps a business can take is to establish a single point of ...
Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales.
A major cyberattack on CDK Global, a software service used by thousands of car dealerships, is now impacting the public. The ...
The night before June 19, Brian MacDonald attended a hockey game. The CDK Global CEO owns a home in Florida, and he capped his day driving two hours to see the Florida Panthers face off against ...
DelveInsight's CDK 7 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, ...